DNA
Ginkgo Bioworks Holdings, Inc.
Key Financials
Net Income
$-312763000
↑ 42.8%
Revenue
$170.2M
↓ 25.1%
Operating Income
$-315278000
↑ 43.7%
Total Liabilities
$611.1M
↓ 7.6%
Total Assets
$1.1B
↓ 18.7%
Shareholders' Equity
$508.6M
↓ 29.0%
EPS (Diluted)
$-5.64
↑ 46.5%
Operating Cash Flow
$-171059000.00
↑ 46.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 144 | 5/13/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEFA14A | 4/29/2026 | View on SEC |
| DEF 14A | 4/29/2026 | View on SEC |
| 4 | 4/20/2026 | View on SEC |
| 144 | 4/17/2026 | View on SEC |
| 144 | 4/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DNA |
| Company Name | Ginkgo Bioworks Holdings, Inc. |
| CIK | 1830214 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Accelerated filer |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (877) 442-5362 |